Evaluating Remdesivir for Severe COVID-19: Efficacy, Safety, and Combination Therapy Insights
- This review evaluates how effective remdesivir is alone and with other drugs.
- Research Design and Methods We searched five databases, including PubMed and Cochrane Library, until April 1, 2022.
- Results showed that remdesivir reduced mortality rates in patients with severe COVID-19 (RR = 0.57, 95% CI: 0.48 to 0.68).
Background
Remdesivir is a drug used to treat COVID-19. This review evaluates how effective remdesivir is alone and with other drugs.
Research Design and Methods
We searched five databases, including PubMed and Cochrane Library, until April 1, 2022. We included randomized controlled trials (RCTs) and observational studies that compared remdesivir alone and in combination with other drugs against control drugs.
Results
We analyzed ten RCTs and 32 observational studies. Results showed that remdesivir reduced mortality rates in patients with severe COVID-19 (RR = 0.57, 95% CI: 0.48 to 0.68). It also shortened the time to clinical improvement (MD = -2.51, 95% CI: -2.75 to -2.28). Furthermore, remdesivir improved clinical status (RR = 1.08, 95% CI: 1.01 to 1.17). Safety assessments indicated that remdesivir did not harm the liver or kidneys (RR = 0.87, 95% CI: 0.68 to 1.11 and RR = 0.88, 95% CI: 0.70 to 1.10). Combining remdesivir with other drugs, such as steroids or convalescent plasma, did not improve mortality.
Conclusion
Remdesivir can lower mortality and speed up recovery in severe COVID-19 cases. However, combination therapy with remdesivir does not offer added benefits for other outcomes.
Trial Registration
PROSPERO registration number: CRD42022322859.